Is HER2+ Metastatic Breast Cancer Curable? What Comes Next – Dr. Gregory Vidal & Dr. Nusayba Bagegni

Recorded live with Drs. Gregory Vidal and Nusayba Bagegni, this in-depth conversation tackles one of the most provocative questions in HER2-positive metastatic breast cancer today: are we finally approaching cure?

The discussion spans more than a decade of progress — from the CLEOPATRA regimen and its long tail of durable responders to the practice-changing data from DESTINY-Breast09 showing a 40-month progression-free survival with T-DXd plus pertuzumab.

The panel explores how Patina, HER2CLIMB-05, endocrine therapy integration, CNS disease, and patient-specific risk factors are reshaping first-line decision-making. With more options than ever before, this episode highlights why precision, sequencing, and shared decision-making now define HER2-positive care.